Report Contents
Market Overview
The global Diabetes Care Devices market is entering a sustained expansion phase, with revenues projected to reach USD 49,20 Billion in 2026 and grow at a compound annual growth rate of 7.80% through 2032, ultimately approaching USD 76,90 Billion. This trajectory builds on the 2025 market size of USD 45,60 Billion and reflects escalating prevalence of diabetes, rising adoption of continuous glucose monitoring, and broader integration of connected insulin delivery systems into everyday clinical practice.
Success in this market increasingly depends on three core strategic imperatives: scalability to support large, chronic patient cohorts; localization of products, reimbursement models, and care pathways to fit diverse regulatory and health system environments; and deep technological integration that links glucose monitoring, insulin delivery, and decision-support software into unified digital therapeutics ecosystems. Converging trends in telehealth, AI-driven analytics, and value-based care are expanding the market’s scope beyond hardware into data services and remote patient management, redefining the competitive landscape. This report positions itself as an essential strategic tool, offering forward-looking analysis to guide capital allocation, partnership strategies, portfolio prioritization, and risk management as the industry undergoes rapid transformation.
Market Growth Timeline (USD Billion)
Source: Secondary Information and ReportMines Research Team - 2026
Market Segmentation
The Diabetes Care Devices Market analysis has been structured and segmented according to type, application, geographic region and key competitors to provide a comprehensive view of the industry landscape.
Key Product Application Covered
Key Product Types Covered
Key Companies Covered
By Type
The Global Diabetes Care Devices Market is primarily segmented into several key types, each designed to address specific operational demands and performance criteria.
-
Self-Monitoring Blood Glucose Devices:
Self-monitoring blood glucose devices currently represent one of the most widely adopted categories in the diabetes care devices market, driven by their central role in daily glycemic control for both type 1 and type 2 diabetes patients. These devices, which include handheld meters and companion test strips, dominate home-based monitoring because they are relatively low cost, easy to use, and available across pharmacies and retail channels globally. Their established installed base means that a significant portion of recurring revenue comes from consumables, creating a stable and predictable demand pattern aligned with the growing global diabetes population.
The core competitive advantage of self-monitoring blood glucose devices lies in their affordability and fast turnaround time, with many modern meters delivering readings in about 5–10 seconds and requiring only micro-liter sample volumes. Compared with older legacy meters that demanded larger blood samples and longer processing times, newer-generation devices can reduce per-test time by an estimated 30–40%, improving adherence for patients who test multiple times daily. Growth is being fueled by the rising prevalence of type 2 diabetes in emerging markets and by reimbursement frameworks that still strongly favor low-cost capillary testing over higher-priced continuous solutions, especially in cost-sensitive health systems.
Another key growth catalyst for self-monitoring blood glucose devices is integration with digital health platforms, which allows automatic data logging and trend analysis without significantly increasing hardware costs. Bluetooth-enabled meters that sync with mobile apps enable patients and clinicians to review multi-week profiles instead of isolated readings, improving therapy adjustments and glycemic outcomes. As healthcare payers increasingly link reimbursement to measurable outcomes, meters that demonstrate improved time-in-range or reduced hypoglycemic events by even 10–15% gain a measurable market advantage, reinforcing the segment’s continued relevance despite the rise of continuous glucose monitoring technologies.
-
Continuous Glucose Monitoring Devices:
Continuous glucose monitoring devices occupy a rapidly expanding, innovation-driven segment of the diabetes care devices market, particularly among intensive insulin users and technology-oriented patients. These systems provide real-time or near–real-time interstitial glucose readings, typically every 1–5 minutes, creating a comprehensive glycemic profile that self-monitoring blood glucose devices cannot match. Their growing market share is especially evident in developed regions, where a significant portion of type 1 diabetes patients has already transitioned or is in the process of transitioning toward sensor-based continuous monitoring.
The primary competitive advantage of continuous glucose monitoring devices is their ability to track time-in-range, glucose variability, and nocturnal hypoglycemia with high granularity, often reducing severe hypoglycemic events by an estimated 30–50% in intensively managed patients. Many leading systems now deliver mean absolute relative differences in the 8–10% range, a meaningful improvement over earlier generations that often exceeded 15%. These accuracy gains, combined with wearable sensors that last 10–14 days or longer, lower the per-day monitoring burden and enhance patient comfort, thereby improving overall adherence to glucose monitoring regimens.
The major catalyst driving continuous glucose monitoring adoption is the convergence of sensor miniaturization, smartphone connectivity, and more favorable reimbursement policies in key markets. As payers increasingly recognize the long-term cost savings from reduced hospitalizations and complication rates, coverage for continuous glucose monitoring has expanded to additional patient segments, including some non–insulin-treated individuals with high-risk profiles. Integration with insulin pumps and automated insulin delivery algorithms further accelerates growth, as closed-loop or hybrid closed-loop systems can increase time-in-range by roughly 10–20 percentage points compared with traditional therapy, making continuous glucose monitoring a foundational technology for next-generation diabetes management.
-
Insulin Pens:
Insulin pens constitute a mature yet steadily growing segment within the diabetes care devices market, serving as a primary delivery modality for insulin-dependent type 2 patients and a substantial share of type 1 patients. These devices have largely replaced traditional vials and syringes in many developed markets due to their dosing convenience, portability, and reduced risk of dosing errors. As populations age and lifestyle-related diabetes continues to rise, insulin pens maintain a strong market position because they streamline daily injection routines and support better adherence compared with less user-friendly formats.
The key competitive advantage of insulin pens is their dosing precision and user-centric design, with many devices allowing dose increments as small as 0.5–1.0 units and incorporating clear dose counters and tactile feedback. Compared with vial-and-syringe regimens, pens can reduce preparation time per injection by an estimated 30–40%, minimizing interruptions to patients’ daily activities. Additionally, disposable prefilled pens reduce contamination risk and drug wastage, improving overall treatment efficiency for both patients and healthcare systems.
Growth in the insulin pen segment is driven by expanding availability of biosimilar insulins and combination therapies packaged in pen formats, which lower treatment costs and encourage switching from traditional delivery methods. Health systems in emerging markets increasingly favor pens as they balance cost-effectiveness with improved patient satisfaction and lower training burdens for healthcare professionals. As manufacturers introduce pens with smoother injection mechanisms and broader dose ranges to accommodate concentrated insulin formulations, uptake is expected to accelerate among patients requiring high daily insulin volumes while still seeking discreet, mobile-friendly dosing solutions.
-
Insulin Pumps:
Insulin pumps represent a high-value, technology-intensive segment of the diabetes care devices market, primarily focused on type 1 diabetes patients and selected insulin-intensive type 2 cases. These devices deliver continuous subcutaneous insulin infusion, enabling more physiological basal-bolus therapy compared with multiple daily injections. Although insulin pumps serve a smaller patient population than pens or syringes, they account for a disproportionately large share of revenue due to their higher device costs and associated consumables such as infusion sets and reservoirs.
The competitive advantage of insulin pumps lies in their capacity to fine-tune insulin delivery with programmable basal rates and bolus calculators, improving glycemic control and reducing long-term complication risks. Modern pumps can deliver insulin in increments as low as 0.025–0.05 units, offering significantly finer control than most pen-based regimens. Clinical use of pump therapy has been associated with reductions in HbA1c of roughly 0.5–1.0 percentage points in suitable patients, along with lower incidence of severe hypoglycemic episodes, which collectively enhance quality of life and long-term health outcomes.
The primary catalyst for growth in this segment is the integration of insulin pumps with continuous glucose monitoring systems to create hybrid closed-loop and automated insulin delivery platforms. These systems can increase time-in-range by an estimated 10–20 percentage points compared with traditional pump therapy without automation, making them especially attractive to pediatric and young adult populations. In addition, the emergence of smaller tubeless patch pumps is lowering barriers to adoption for users who previously rejected pumps due to aesthetic or lifestyle concerns, further expanding the addressable market for advanced insulin delivery solutions.
-
Smart Insulin Pens:
Smart insulin pens occupy an emerging, digitally enabled niche within the diabetes care devices market, bridging traditional injection-based therapy and fully automated insulin delivery systems. These devices augment standard pens with connectivity and embedded electronics to log doses, calculate bolus recommendations, and transmit data to companion apps or clinician dashboards. Their adoption is particularly strong among tech-savvy type 1 and insulin-treated type 2 patients who seek better glycemic control but are not ready or eligible for pump therapy.
The core competitive advantage of smart insulin pens lies in their ability to reduce missed or duplicate doses and improve dosing accuracy without significantly changing patients’ existing injection routines. By tracking injection time, insulin type, and dose quantity, smart pens can help cut dose-related errors by an estimated 20–30% compared with manual logging or memory-based approaches. They also support advanced decision support, such as calculating correction boluses based on real-time glucose readings imported from continuous glucose monitoring systems or self-monitoring blood glucose meters, thereby improving insulin titration quality.
Growth is being catalyzed by the expansion of interoperable digital ecosystems, where smart pens are integrated into broader diabetes management platforms that combine glucose data, insulin history, diet logs, and activity metrics. As payers and providers push for data-driven care models, smart pen systems that demonstrate measurable improvements in HbA1c and time-in-range, even by modest margins of 5–10%, gain traction as a cost-effective alternative to pump therapy. Additionally, pharmaceutical companies increasingly bundle smart pen solutions with insulin formulations, using connected hardware as a differentiation tool in competitive insulin markets and thereby driving uptake.
-
Insulin Syringes:
Insulin syringes remain a foundational, cost-sensitive segment of the diabetes care devices market, particularly prevalent in low- and middle-income regions where affordability and basic accessibility outweigh convenience and advanced features. Despite competition from pens and pumps, syringes continue to be widely used for both basal and bolus insulin delivery, especially in institutional settings and among patients with limited insurance coverage. Their entrenched presence ensures steady baseline demand, even as higher-income markets gradually shift toward more advanced delivery formats.
The main competitive advantage of insulin syringes is their very low unit cost and broad compatibility with nearly all vial-based insulin formulations, making them a flexible option for budget-constrained health systems. Syringes are available in multiple barrel sizes and needle gauges, allowing dosing increments as small as 0.5 units when appropriately calibrated. While they may not reduce dosing errors as effectively as pens or pumps, their direct and transparent measurement scales allow trained patients and healthcare professionals to maintain acceptable accuracy for many treatment regimens at a fraction of the per-dose hardware cost.
The key growth driver for insulin syringes is continued diabetes prevalence in regions where healthcare infrastructure and reimbursement for advanced devices remain limited. In many public-sector procurement programs, syringes represent the default insulin delivery device because they can be purchased in bulk and distributed through primary care clinics at minimal marginal cost. Regulatory efforts to standardize needle safety and reduce accidental needle-stick injuries, including the adoption of safety-engineered syringes, may also support incremental value growth by encouraging upgrades to improved syringe designs within existing syringe-dependent patient populations.
-
Lancets and Lancing Devices:
Lancets and lancing devices form a critical consumables segment of the diabetes care devices market, closely tied to self-monitoring blood glucose usage. Every capillary blood test typically requires a sterile lancet, which drives high-volume, recurring demand across the installed base of blood glucose meters. Although unit prices are low, cumulative consumption over years of daily testing represents a significant revenue stream for manufacturers and distributors, particularly in regions with high testing frequency.
The competitive advantage of modern lancing devices lies in their ability to minimize pain and tissue damage while ensuring adequate sample volume, thereby improving patient adherence to frequent testing. Advanced devices offer multiple depth settings and engineered needle tips designed to reduce penetration force by an estimated 20–30% compared with older designs. This reduction in discomfort can increase willingness to test the recommended number of times per day, which is crucial for patients using intensive insulin regimens that may require 4–8 fingersticks daily.
Growth in this segment is driven by ongoing improvements in needle technology and user-friendly device ergonomics, as well as the expansion of diabetes screening and community-based monitoring programs. Even as continuous glucose monitoring adoption increases, a substantial proportion of patients still rely on fingerstick testing, and continuous glucose monitoring users often need lancets for calibration or confirmation of extreme values. Moreover, bundling strategies where lancing devices are packaged with glucometers or starter kits help lock in brand loyalty and sustain demand for compatible lancet refills over the long term.
-
Diabetes Management Software and Apps:
Diabetes management software and apps represent a fast-growing digital health segment within the diabetes care devices market, connecting hardware devices with cloud-based analytics and care coordination tools. These platforms aggregate data from continuous glucose monitoring systems, self-monitoring blood glucose meters, insulin pens, pumps, and wearable fitness trackers into unified dashboards. They increasingly influence treatment decisions by allowing patients and clinicians to visualize trends, identify patterns, and adjust therapy regimens in near real time.
The primary competitive advantage of diabetes management software and apps lies in their ability to transform raw device data into actionable insights, often through algorithms that flag high-risk patterns or suggest dose adjustments. Studies across digital platforms have shown that structured data review and remote coaching can reduce HbA1c by roughly 0.5–1.0 percentage points in engaged user populations, while also lowering acute event rates such as severe hypoglycemia or diabetic ketoacidosis. Many solutions also support telemedicine workflows, enabling clinicians to remotely monitor dozens or hundreds of patients simultaneously, significantly improving care team productivity compared with traditional in-person-only visits.
The major growth catalyst for this segment is the global shift toward value-based care and remote monitoring, accelerated by broader adoption of telehealth infrastructure. Payers and providers increasingly seek software platforms that can document time-in-range improvements, reduce emergency admissions, and support population-level risk stratification, making robust analytics and interoperability critical purchasing criteria. As diabetes management apps integrate with electronic health records and expand beyond glucose metrics to include blood pressure, lipid profiles, and medication adherence, they position themselves as central operating systems for chronic disease management rather than standalone adjuncts, further increasing their strategic importance within the overall diabetes care ecosystem.
-
Sensor-Based Insulin Delivery Systems:
Sensor-based insulin delivery systems, often referred to as hybrid closed-loop or automated insulin delivery solutions, occupy the cutting edge of the diabetes care devices market. These systems combine continuous glucose monitoring sensors with insulin pumps and control algorithms that automatically adjust basal insulin delivery and sometimes deliver correction boluses. The segment targets intensively managed type 1 patients and select high-risk type 2 patients, offering an integrated approach that reduces the cognitive burden of constant diabetes decision-making.
The competitive advantage of sensor-based insulin delivery systems is their ability to substantially improve glycemic metrics with minimal user intervention, often increasing time-in-range to 70–75% or higher in many users compared with 50–60% under traditional therapies. Automation can reduce overnight hypoglycemia rates by an estimated 40–60%, providing tangible safety and quality-of-life benefits. These outcomes are driven by control algorithms that process glucose data every few minutes and adjust insulin delivery in small increments, a level of responsiveness impossible to match with manual dosing approaches.
Growth in this segment is propelled by continuous algorithm refinement, improved sensor accuracy, and stronger reimbursement support in high-income markets. Regulatory approvals of new generations of automated systems validate their clinical effectiveness and encourage wider uptake among endocrinologists and diabetes centers. As systems become more interoperable, allowing patients to pair different pumps and sensors under standardized communication protocols, the addressable market expands and competitive innovation accelerates. The promise of further reducing user input, potentially approaching fully closed-loop control, remains a powerful catalyst attracting both patients and investors to this segment.
-
Blood Glucose Test Strips:
Blood glucose test strips are a high-volume consumable core to the economics of the self-monitoring blood glucose segment within the diabetes care devices market. Each blood glucose measurement typically requires a single-use strip, resulting in thousands of strips consumed over the lifetime of a single patient using intensive self-monitoring. Because strips are required for every test, they often account for a substantial portion of total monitoring costs for both patients and healthcare systems, especially in markets where continuous glucose monitoring is not yet widely adopted.
The competitive advantage of blood glucose test strips is closely tied to their analytical accuracy, lot-to-lot consistency, and chemical stability, which directly impact therapeutic decisions. Modern strips are designed to provide results with accuracy that meets or surpasses international standards, aiming to keep 95% or more of readings within defined error margins relative to laboratory references. Manufacturing innovations have reduced blood volume requirements to as low as 0.3–0.5 microliters for some brands, while also shortening reaction times, leading to faster and more comfortable testing experiences that encourage adherence.
Growth dynamics for blood glucose test strips are shaped by competing trends: on one hand, rising global diabetes prevalence and continued reliance on self-monitoring blood glucose sustain baseline demand; on the other hand, continuous glucose monitoring adoption gradually reduces strip usage per patient in technologically advanced markets. However, in many regions, particularly low- and middle-income countries, strips remain the primary quantitative monitoring tool and benefit from government procurement programs and insurance reimbursement. Competitive pricing, local manufacturing, and value-oriented packaging, such as multi-hundred-strip packs, are key levers that manufacturers use to maintain and expand market share in this essential consumables category.
Market By Region
The global Diabetes Care Devices market demonstrates distinct regional dynamics, with performance and growth potential varying significantly across the world's major economic zones.
The analysis will cover the following key regions: North America, Europe, Asia-Pacific, Japan, Korea, China, USA.
-
North America:
North America represents a core profit pool for diabetes care devices, anchored by advanced reimbursement frameworks and high adoption of continuous glucose monitoring and insulin pump systems. The United States and Canada act as the primary demand centers, supported by large diagnosed diabetic populations and strong endocrinology networks. The region accounts for a significant portion of the global market, providing a mature, recurring revenue base that stabilizes worldwide demand and underpins premium pricing for innovative hardware and software-enabled devices.
Despite its maturity, North America still offers untapped potential in Medicaid-heavy states, low-income urban communities and remote rural areas where penetration of connected glucometers and digital coaching tools remains limited. Key challenges include addressing reimbursement disparities, mitigating out-of-pocket costs and improving integration between devices and electronic health records. Companies that bundle devices with value-based care programs and remote patient monitoring services are well positioned to unlock incremental growth in this region.
-
Europe:
Europe is strategically important due to its large installed base of insulin users and strong emphasis on evidence-based procurement by public health systems. Germany, the United Kingdom, France and the Nordics are the main growth engines, with high utilization of smart insulin pens, flash glucose monitoring and cloud-connected data platforms. The region contributes a substantial share of global revenue, characterized by stable, contract-driven purchasing cycles and rigorous health technology assessments that shape global pricing benchmarks.
Untapped potential lies in Southern and Eastern European markets, where adoption of advanced diabetes care devices lags due to constrained healthcare budgets and fragmented reimbursement structures. Rural populations and aging cohorts often rely on legacy fingerstick systems rather than continuous monitoring. Overcoming regulatory heterogeneity, demonstrating cost-effectiveness in real-world outcomes and building local training capabilities for primary care providers are critical to expanding device penetration and capturing additional share from traditional monitoring approaches.
-
Asia-Pacific:
Asia-Pacific is a pivotal high-growth corridor for diabetes care devices, driven by rapid urbanization, rising obesity rates and expanding middle-class access to private healthcare. Major contributors include India, Australia, Southeast Asian economies and emerging markets such as Indonesia and Vietnam. The region is estimated to account for a growing portion of the global market, functioning primarily as an expansion engine that will accelerate overall industry growth beyond the global CAGR of 7.80 percent projected by ReportMines.
Untapped potential is substantial across public hospitals and primary care clinics, where many patients remain on basic glucometers with limited data connectivity. Rural populations often lack consistent supply chains for test strips and sensors, constraining adherence and device utilization. Key challenges involve price sensitivity, uneven reimbursement and limited specialist infrastructure. Scalable opportunities exist for lower-cost sensor technologies, subscription-based device packages and tele-endocrinology models tailored to large, distributed patient populations.
-
Japan:
Japan occupies a distinct niche in the global diabetes care devices landscape, combining a rapidly aging population with strong domestic manufacturing capabilities and stringent quality expectations. The country is a regional leader in advanced insulin delivery systems and highly accurate glucose monitoring devices, supported by sophisticated hospital networks and technology-oriented consumers. Japan contributes a meaningful, though not dominant, share of global revenues, serving as a reference market for precision engineering and user-friendly device design.
However, opportunities remain in expanding device use beyond specialist centers into community clinics and home-care settings, particularly for elderly patients managing multiple comorbidities. Challenges include conservative prescribing patterns, complex regulatory pathways and pressure to control healthcare spending. Companies that can integrate devices with home nursing services, remote monitoring dashboards and caregiver-friendly interfaces can capture additional demand and improve adherence in this aging, high-risk population.
-
Korea:
Korea is emerging as a technologically advanced hub in the diabetes care devices market, underpinned by strong broadband infrastructure, high smartphone penetration and a government focus on digital health. The market is largely driven by South Korea, which supports rapid uptake of app-connected glucometers, smart insulin delivery solutions and AI-driven analytics. While its global share is moderate, Korea punches above its weight as an early adopter environment that can validate new digital device ecosystems before broader Asia-Pacific rollout.
Significant untapped potential exists in integrating diabetes devices with national health insurance data and hospital information systems to enable proactive population health management. Barriers include reimbursement constraints for newer device categories, competition from low-cost imports and concerns about data privacy. Strategic opportunities arise for partnerships between device manufacturers, telecom operators and hospital groups to create bundled remote monitoring programs that can be scaled nationally and exported to neighboring markets.
-
China:
China is one of the most strategic high-volume markets for diabetes care devices, driven by a large and growing diabetic population and rapid expansion of urban healthcare infrastructure. Tier 1 and Tier 2 cities are leading adopters of connected glucometers, continuous glucose monitoring systems and digital coaching platforms, supported by private hospitals and online pharmacies. China’s share of global demand is increasing steadily, making it a critical contributor to overall growth within the 2025 to 2032 forecast window defined by ReportMines.
Despite this momentum, a significant portion of the diabetic population in lower-tier cities and rural provinces remains underdiagnosed and underserved, relying on basic or inconsistent monitoring. Key obstacles include affordability gaps, regional disparities in reimbursement and varying regulatory requirements across provinces. Companies can unlock major upside by developing cost-optimized devices, partnering with internet hospitals and leveraging e-commerce channels to expand access to sensors, strips and integrated disease management solutions.
-
USA:
The USA is the single most influential national market for diabetes care devices, with high per-capita healthcare spending and strong demand for premium continuous glucose monitoring and advanced insulin pump platforms. It anchors a large portion of global revenues and heavily influences product roadmaps, due to its scale, venture-backed innovation ecosystem and sophisticated payer landscape. Commercial insurers, Medicare and employer-sponsored plans create diverse reimbursement pathways that support rapid adoption of clinically differentiated devices.
Nonetheless, substantial untapped potential persists among uninsured and underinsured populations, as well as in community health centers that still rely on older monitoring technologies. Cost-sharing burdens, formularies and prior authorization requirements remain key friction points. Strategic growth opportunities center on value-based contracting, patient-assistance programs, and integrated platforms that connect devices to telehealth visits and pharmacy services, thereby improving adherence and expanding long-term device utilization across demographic segments.
Market By Company
The Diabetes Care Devices market is characterized by intense competition, with a mix of established leaders and innovative challengers driving technological and strategic evolution.
-
F. Hoffmann-La Roche Ltd:
F. Hoffmann-La Roche Ltd holds a prominent position in the Diabetes Care Devices market through its long-standing Accu-Chek portfolio of blood glucose monitoring systems, digital diabetes management tools, and connected ecosystem solutions. The company leverages its global diagnostic infrastructure to integrate point-of-care testing, lab analytics, and patient self-monitoring, which reinforces its relevance across both clinical and home-care diabetes pathways. Its broad installed base and strong relationships with endocrinologists, diabetologists, and primary care providers help maintain high switching costs for institutional customers.
In 2025, Roche’s diabetes care devices business is estimated to generate revenue of USD 5.20 billion with a market share of approximately 11.40% of the global Diabetes Care Devices market. This revenue scale indicates that Roche remains one of the top-tier incumbents in glucose monitoring, particularly in regions where capillary blood glucose testing remains prevalent and reimbursement for newer continuous glucose monitoring technologies is still evolving. The market share reflects robust penetration in Europe, Latin America, and parts of Asia, though competitive pressure from sensor-based systems is gradually reshaping the mix.
These figures highlight Roche’s role as a high-volume, moderately high-margin player that balances legacy strip-based monitoring revenue with gradual migration toward connected meters and digital platforms. The company’s competitiveness relies on its manufacturing scale in test strips, strong distribution networks, and ongoing upgrades to Bluetooth-enabled meters and data-sharing apps. Although growth rates in traditional blood glucose monitoring are slower than sensor-based segments, Roche’s installed base of millions of users provides recurring consumables revenue and a sizable data asset for analytics-driven care optimization.
Strategically, F. Hoffmann-La Roche differentiates itself through integration of diabetes diagnostics with broader chronic disease management and laboratory solutions. Its core capabilities include assay development, high-throughput manufacturing of test strips, and regulatory expertise across more than one hundred countries. By leveraging these strengths, Roche can offer bundled solutions to health systems that combine glucose monitoring, cardiovascular risk testing, and other metabolic diagnostics under unified contracts. Compared with pure-play device competitors, Roche benefits from cross-selling opportunities, but it must continue accelerating its transition toward sensor, app, and cloud-based diabetes care models to defend share against more agile CGM innovators.
-
Abbott Laboratories:
Abbott Laboratories is one of the most influential companies in the Diabetes Care Devices market, primarily due to its FreeStyle Libre continuous glucose monitoring platform. The company has transformed glucose monitoring from fingerstick-driven workflows into factory-calibrated sensor-based systems that enable real-time and retrospective glucose analytics. Abbott’s rapid global rollout of Libre, spanning developed markets and several emerging economies, has meaningfully expanded access to CGM technology beyond intensive insulin users into broader type 2 diabetes cohorts.
In 2025, Abbott’s diabetes care devices revenue is projected to reach approximately USD 9.10 billion, corresponding to a market share of about 19.96%. This performance positions Abbott as one of the largest players in the global Diabetes Care Devices market, reflecting both high volume sensor adoption and recurring revenue from consumable wearables. The numbers indicate a strong growth profile compared with the overall market CAGR of 7.80%, suggesting that Abbott continues to outpace category growth through increased penetration in type 2 diabetes, expanded sensor indications, and reimbursement wins.
Abbott’s scale and competitiveness stem from its ability to offer a relatively affordable, easy-to-use CGM platform that minimizes calibration complexity and integrates with smartphones and connected insulin delivery systems. The FreeStyle Libre ecosystem generates large volumes of real-world data, which Abbott uses to refine algorithms, customize alerts, and support population-level diabetes management programs. This data-centric approach enhances the company’s strategic relevance to payers and health systems looking to reduce hospitalization rates and diabetes-related complications.
Compared with many competitors, Abbott’s strategic advantages include high-capacity sensor manufacturing, strong payer engagement, and a broad geographic footprint that spans North America, Europe, and rapidly growing markets in Asia-Pacific and Latin America. The company continues to invest in next-generation biosensing, interoperability with insulin pumps and pens, and integration with digital therapeutics. As more health systems adopt time-in-range and other CGM-driven metrics as clinical endpoints, Abbott’s installed base and ecosystem integration create high switching costs and reinforce its leadership in the Diabetes Care Devices segment.
-
Medtronic plc:
Medtronic plc is a core leader in the Diabetes Care Devices market, especially in insulin pump therapy and integrated continuous glucose monitoring systems. The company’s MiniMed insulin pumps and associated sensor technologies target intensive insulin users who require precise, closed-loop or hybrid closed-loop insulin delivery. Medtronic has historically set benchmarks in automated insulin delivery algorithms and sensor-pump integration, positioning itself as a pivotal player in advanced diabetes technology.
For 2025, Medtronic’s diabetes segment revenue is estimated at USD 4.30 billion, representing an approximate market share of 9.43% of the global Diabetes Care Devices market. This revenue and share profile demonstrates Medtronic’s strong presence in high-acuity patient segments, even though its overall share is distributed across pump hardware, consumables, and CGM sensors. The figures indicate that Medtronic remains highly competitive in technology-intensive subsegments, while facing intensifying competition from newer pump and CGM entrants.
Medtronic’s market positioning benefits from its depth in algorithm development, encompassing predictive low-glucose suspend and increasingly automated basal and bolus dosing. Its integrated systems appeal to payers and providers who seek comprehensive therapy solutions, including patient education, remote monitoring, and technical support. However, regulatory timelines and product update cycles have at times allowed nimble competitors to introduce newer user interfaces and connectivity features more quickly, which Medtronic is addressing through accelerated innovation and cloud-based data platforms.
The company’s strategic advantages center on its engineering capabilities, clinical evidence base, and long-standing relationships with endocrinology centers that manage complex type 1 diabetes populations. By integrating pumps, sensors, and data platforms, Medtronic can deliver end-to-end therapy management that supports value-based care contracts. The firm’s focus on international expansion and adaptation of platforms for different reimbursement environments positions it to capture growth as more health systems shift toward advanced insulin delivery technologies.
-
Dexcom Inc.:
Dexcom Inc. is a specialist and innovation leader in real-time continuous glucose monitoring technologies within the Diabetes Care Devices market. The company has built its reputation on high-accuracy CGM sensors that provide continuous readings, customizable alerts, and seamless integration with smartphones and insulin delivery devices. Dexcom’s platforms are widely used by type 1 diabetes patients and increasingly by insulin-intensive type 2 users, helping to reduce hypoglycemia risk and improve glycemic variability.
In 2025, Dexcom’s revenue from diabetes care devices is projected at approximately USD 4.00 billion, with an estimated market share of 8.79%. These figures underscore the company’s strong growth trajectory, especially given that the overall Diabetes Care Devices market is expected to reach USD 45.60 billion in 2025 with a 7.80% CAGR through 2032. Dexcom’s share reflects its high penetration in North America and Europe, along with rapidly expanding adoption in Asia-Pacific through new product launches and strategic partnerships.
Dexcom’s competitiveness derives from its sensor accuracy, sensor wear duration, and interoperability with multiple insulin pumps and smart insulin pens. The company has strategically positioned its CGM systems as a digital health platform rather than a stand-alone device, emphasizing remote patient monitoring, clinician dashboards, and data-sharing with caregivers. This approach supports broader adoption in telehealth and virtual diabetes clinics, which increasingly rely on CGM data to adjust therapy between in-person visits.
Compared with diversified device companies, Dexcom’s focused R&D investment in biosensor chemistry, signal processing, and wireless connectivity allows it to iterate quickly and maintain technological leadership. The company’s strategic collaborations with insulin pump manufacturers and software developers further differentiate its ecosystem and create high switching barriers. As CGM becomes standard of care for more segments of the diabetic population, Dexcom is positioned to capture a significant portion of incremental sensor demand and to play a central role in value-based diabetes management programs.
-
Insulet Corporation:
Insulet Corporation is a key innovator in the Diabetes Care Devices market through its tubeless insulin pump platform, which is designed to improve user convenience and lifestyle flexibility. The company’s wearable patch pump technology targets both type 1 and insulin-requiring type 2 diabetes patients who prefer discreet, on-body insulin delivery without traditional tubing. This differentiated design has helped Insulet capture patients who might otherwise remain on multiple daily injections due to concerns about pump complexity or body image.
For 2025, Insulet’s diabetes-related revenue is estimated at USD 2.20 billion, giving the company an approximate market share of 4.82% in the global Diabetes Care Devices market. These numbers reflect rapid, above-market growth driven by expansion in the United States, Europe, and selected Asia-Pacific markets, as well as increased adoption of automated insulin delivery features when integrated with compatible CGM systems. The revenue base remains heavily recurring due to pod consumable usage, which supports attractive long-term unit economics.
Insulet’s strategic positioning centers on user-centric design, simplified onboarding, and scalable manufacturing of disposable pods. Its competitive advantage lies in offering a differentiated form factor that competes more on lifestyle and ease-of-use than solely on advanced insulin algorithms. As the company deepens integration with CGM partners and expands indications for pediatric and type 2 populations, it strengthens its relevance for a broader range of payers and clinician segments.
Compared to traditional pump manufacturers, Insulet benefits from a leaner hardware footprint and a high degree of software-driven functionality, facilitating continuous product enhancement via firmware and app updates. Its growth strategy includes geographic expansion, targeted direct-to-consumer marketing, and partnerships with digital health platforms for remote coaching and data analytics. This combination of product design, ecosystem integration, and recurring consumables revenue supports Insulet’s role as a high-growth challenger within the insulin delivery segment.
-
Novo Nordisk A/S:
Novo Nordisk A/S is primarily recognized as a global leader in diabetes therapeutics; however, it has also expanded into Diabetes Care Devices through smart insulin pens, connected pen caps, and digital adherence solutions. The company leverages its extensive insulin and GLP-1 franchise to integrate devices that capture dosing data and translate it into actionable insights for patients and clinicians. This strategy positions Novo Nordisk at the intersection of pharmacotherapy and connected care, complementing traditional device players.
In 2025, Novo Nordisk’s revenue specifically attributable to Diabetes Care Devices is estimated at USD 1.10 billion, equivalent to a market share of around 2.41%. While this share is smaller than that of pure-play device manufacturers, it is strategically significant because it directly supports the company’s much larger diabetes drug portfolio. The figures indicate that device revenues are less about stand-alone scale and more about enhancing medication adherence, dosing accuracy, and real-world outcomes that underpin drug value propositions.
Novo Nordisk’s competitive differentiation arises from tight integration between its connected pen solutions and its leading insulin and GLP-1 brands. By capturing real-time dosing data and linking it with glucose readings from third-party systems, the company can help clinicians optimize titration, reduce hypoglycemic events, and personalize treatment regimens. This approach has strong appeal for payers implementing outcomes-based contracts, because it provides a more complete picture of therapy adherence and effectiveness.
Strategically, Novo Nordisk’s capabilities in behavioral science, patient support programs, and digital health partnerships allow it to embed devices into broader chronic disease management frameworks. The firm collaborates with software firms, CGM providers, and electronic health record vendors to create seamless data flows. As health systems increasingly value integrated drug-device-care pathways, Novo Nordisk’s device initiatives support its long-term objective of improving population-level diabetes outcomes while reinforcing its pharmaceutical leadership.
-
Sanofi:
Sanofi is another major diabetes pharmaceutical company that participates in the Diabetes Care Devices market through connected insulin pens, titration tools, and digital diabetes management platforms. Historically known for its basal insulin portfolio, Sanofi has invested in device-enabled solutions to differentiate its therapies and provide added value to both patients and payers. Its device strategy focuses on facilitating correct dosing, encouraging adherence, and integrating data into care plans.
For 2025, Sanofi’s device-related diabetes care revenue is estimated at USD 0.80 billion, equating to a market share of approximately 1.76% of the global Diabetes Care Devices market. These figures reveal a smaller scale compared with pure-play device manufacturers, but they underscore the importance of devices as strategic enablers that protect and expand Sanofi’s drug revenues. The market share reflects targeted deployments of connected solutions in markets where digital health infrastructure and reimbursement frameworks are more advanced.
Sanofi’s competitiveness in devices is driven by its ability to design user-friendly connected pens and integrate them with companion apps that support dose reminders, pattern recognition, and clinician communication. The company emphasizes interoperability with various glucose monitoring systems and telemedicine platforms to fit into existing clinical workflows. This creates an ecosystem that helps differentiate Sanofi’s injectable therapies in increasingly crowded therapeutic classes.
Sanofi’s strategic advantages include its global market access capabilities, regulatory experience, and established relationships with primary care and endocrinology practices. By integrating device data into disease management programs and risk-sharing agreements, Sanofi can demonstrate improved adherence and clinical outcomes. This strengthens its negotiating position with payers and health systems and reinforces its relevance in a market where drug efficacy, patient behavior, and device-enabled insights are increasingly interconnected.
-
Becton Dickinson and Company:
Becton Dickinson and Company (BD) plays a critical enabling role in the Diabetes Care Devices market through its portfolio of insulin syringes, pen needles, and safety-engineered injection systems. These products remain essential for a large segment of insulin-treated patients, particularly in regions where pump and CGM penetration remains limited or reimbursement is constrained. BD’s high-volume manufacturing and emphasis on injection comfort and safety have made it a preferred partner for both patients and healthcare providers.
In 2025, BD’s diabetes-related device revenue is estimated at USD 2.00 billion, translating into a global market share of about 4.39%. This share reflects the ubiquity of BD’s injection devices across hospitals, clinics, and home-care settings, as well as its strong presence in both developed and emerging markets. While the growth of advanced technologies such as insulin pumps and CGM may gradually temper needle demand in some segments, a significant portion of the global diabetic population still relies on traditional injection-based therapy.
BD’s competitiveness is anchored in manufacturing scale, product reliability, and continuous improvements in needle design to reduce pain and improve injection technique. The company invests in microneedle technology, safety mechanisms to prevent needlestick injuries, and educational programs to support proper injection practices. These investments have helped BD maintain customer loyalty and defend its share against lower-cost regional competitors.
Strategically, BD’s role in diabetes care is likely to remain important as a complement to more advanced devices. Even as digital and connected platforms expand, there will continue to be large patient segments that require cost-effective, dependable injection solutions. BD’s global distribution network, close collaboration with insulin manufacturers, and strength in clinical training position it to continue capturing recurring revenue while exploring opportunities to integrate its products with digital adherence and monitoring tools.
-
Terumo Corporation:
Terumo Corporation is an important regional and increasingly global participant in the Diabetes Care Devices market, particularly in insulin syringes, pen needles, and infusion sets. The company has a strong presence in Japan and other parts of Asia, and it is steadily expanding its footprint in Europe and other international markets. Terumo focuses on precision engineering, patient comfort, and quality control, which are critical attributes for diabetes injection devices and infusion components.
For 2025, Terumo’s diabetes device revenue is estimated at USD 1.30 billion, equal to a market share of approximately 2.85%. These figures highlight Terumo’s solid mid-tier scale in the global market, with particularly strong shares in selected Asian countries where it benefits from deep local relationships and familiarity with regulatory frameworks. The market share underscores Terumo’s role as both a domestic champion in Japan and a competitive exporter of diabetes consumables.
Terumo’s strategic strengths include high-precision manufacturing of needles and catheters, lean production processes, and a reputation for reliability among clinicians. Its diabetes portfolio integrates with broader offerings in vascular access, infusion therapy, and hospital supplies, enabling the company to negotiate bundled contracts and leverage multi-category purchasing agreements. This integration provides cost and service advantages compared with smaller single-category competitors.
As the Diabetes Care Devices market evolves, Terumo is likely to explore greater integration with digital diabetes management tools and to align its products with emerging home-care and self-administration trends. Its long history in minimally invasive technologies and patient-centric design offers a platform for incremental innovation in diabetes injection and infusion solutions, particularly in fast-growing Asian markets where diabetes prevalence is increasing rapidly.
-
Ypsomed Holding AG:
Ypsomed Holding AG is a specialized diabetes technology company with a strong focus on insulin pump systems and injection device platforms. The firm is known for its modular insulin pump technology, pen systems licensed to pharmaceutical companies, and growing ecosystem of connected diabetes care solutions. Ypsomed has leveraged its engineering expertise to provide both proprietary products and OEM solutions to global pharma and device partners.
In 2025, Ypsomed’s diabetes-related device revenue is estimated at USD 0.90 billion, corresponding to a market share of around 1.98% in the global Diabetes Care Devices market. This scale positions Ypsomed as a focused mid-size player with a strong niche in pen injection systems and emerging insulin pump platforms. The figures signify a company that punches above its size in terms of influence because many leading insulin brands rely on Ypsomed’s device technologies.
Ypsomed differentiates itself through flexible platform designs that can be customized for different pharmaceutical partners and therapy regimens. Its insulin pump solutions emphasize simplicity, modular components, and compatibility with digital monitoring tools, making them attractive to both patients and healthcare providers seeking user-friendly alternatives. The company’s OEM business spreads risk across multiple drug portfolios and geographies, ensuring revenue diversification.
Strategically, Ypsomed’s capabilities in precision plastics, mechatronics, and device industrialization allow it to rapidly bring new diabetes device concepts from design to scaled production. This makes it a preferred partner for pharmaceutical companies seeking to add value through device innovation without building in-house manufacturing. As connected pen and pump ecosystems expand, Ypsomed is well positioned to benefit from demand for integrated, data-enabled injection and infusion systems.
-
Ascensia Diabetes Care:
Ascensia Diabetes Care is a dedicated diabetes device company focused primarily on blood glucose monitoring systems, including meters, test strips, and digital diabetes management tools. Building on the legacy of its Contour brand, Ascensia has developed a global presence, particularly in Europe, North America, and Asia, catering to both type 1 and type 2 diabetes patients who rely on capillary blood glucose testing. The company has also expanded into CGM distribution partnerships in certain markets.
For 2025, Ascensia’s revenue in the Diabetes Care Devices market is estimated at USD 1.40 billion, resulting in a market share of about 3.07%. These figures indicate a strong, though somewhat mature, position in traditional blood glucose monitoring, offset by efforts to participate in the growing CGM segment. The revenue base remains heavily driven by consumables, with test strips providing recurring income streams even as usage patterns evolve due to sensor adoption.
Ascensia’s strategic advantages include high-accuracy meter technology, a broad portfolio tailored to different price points, and well-established distribution channels through pharmacies, hospitals, and clinics. The company has invested in mobile apps and cloud platforms that aggregate glucose readings, generate reports, and support clinician decision-making. This digital layer enhances the value of its meters, particularly in markets where reimbursement for newer technologies remains limited.
Facing increasing competition from CGM players and low-cost strip manufacturers, Ascensia is positioning itself as a hybrid player that bridges legacy and emerging technologies. Its collaborations with CGM innovators and participation in digital health programs allow it to remain relevant as care models shift toward continuous monitoring. This strategic flexibility, combined with a solid installed base, supports its continued role as an important global provider of diabetes monitoring solutions.
-
Tandem Diabetes Care Inc.:
Tandem Diabetes Care Inc. is a high-growth specialist in insulin pump therapy, known for its user-friendly, touchscreen-based pumps and advanced automated insulin delivery algorithms. The company has successfully differentiated itself within the Diabetes Care Devices market through intuitive design, frequent software updates, and strong integration with leading CGM systems. Its platforms primarily target type 1 diabetes patients who require intensive insulin management.
In 2025, Tandem’s diabetes device revenue is estimated at USD 1.60 billion, with a corresponding market share of approximately 3.51%. These figures underscore the company’s rapid expansion from a niche player to a significant competitor in the insulin pump segment. Tandem’s share is concentrated in North America and selected international markets where reimbursement and specialist support for pump therapy are well established.
Tandem’s core competitive strength lies in its software-driven approach to product development. The company frequently enhances pump functionality via remote software upgrades, allowing existing users to benefit from new algorithms without hardware replacement. This model builds customer loyalty and supports a subscription-like relationship based on continuous innovation. Integration with leading CGM platforms enables Tandem to offer hybrid closed-loop systems that automatically adjust insulin dosing based on real-time glucose levels.
Strategically, Tandem focuses on strengthening its clinical evidence base, expanding indications across age groups, and improving its manufacturing capacity to meet rising demand. Collaborations with diabetes clinics, advocacy groups, and digital health providers help the company reach new patients and support long-term adherence. As automated insulin delivery becomes more mainstream, Tandem’s technology leadership and user-centric design provide a solid foundation for growth and ongoing competitive differentiation.
-
LifeScan Inc.:
LifeScan Inc. is a long-established participant in the Diabetes Care Devices market, best known for its OneTouch blood glucose monitoring systems. The company serves a broad base of type 1 and type 2 diabetes patients who rely on fingerstick testing for daily glucose management. LifeScan has transitioned from being part of a larger healthcare conglomerate to operating as a focused diabetes solutions company with an emphasis on digital engagement and patient support.
In 2025, LifeScan’s diabetes device revenue is estimated at USD 1.80 billion, yielding a market share of around 3.95%. These numbers demonstrate LifeScan’s continued scale in the blood glucose monitoring segment, supported by recurring test strip sales and strong brand recognition. Although overall growth in traditional BGM is modest, LifeScan’s installed base and extensive distribution keep it highly relevant, particularly in markets where CGM adoption remains limited.
LifeScan differentiates itself through user-friendly meters, wide reimbursement coverage, and a growing suite of digital tools that help patients interpret their readings and modify behaviors. The company has invested in mobile apps, coaching programs, and partnerships with health insurers and digital health platforms to extend its role beyond hardware into broader diabetes self-management. This approach helps maintain engagement with patients even as emerging technologies reshape the market landscape.
Strategically, LifeScan’s ability to deliver reliable, cost-effective monitoring at scale positions it as a key partner for population-level diabetes management programs. Health systems and payers often include OneTouch solutions in formularies and bundled care pathways due to their affordability and proven track record. LifeScan’s challenge and opportunity lie in leveraging its data and customer relationships to participate more fully in connected care models and value-based contracts.
-
Senseonics Holdings Inc.:
Senseonics Holdings Inc. is a niche innovator in the Diabetes Care Devices market, focusing on implantable continuous glucose monitoring systems. Its long-term sensor, designed to be implanted subcutaneously and used for several months, offers a differentiated alternative to traditional transcutaneous CGM devices. This approach targets patients who seek reduced insertion frequency and greater convenience, supported by external transmitters and smartphone apps for data visualization.
For 2025, Senseonics’ revenue is estimated at USD 0.25 billion, corresponding to a global market share of about 0.55%. While this share is relatively small compared with large CGM players, it reflects the early-stage yet growing adoption of implantable CGM technology in selected markets. The revenue base is concentrated in regions where regulatory approvals and reimbursement frameworks support the implantable model, often in collaboration with distribution partners.
Senseonics’ competitive edge lies in its differentiated technology, which reduces the need for frequent sensor replacements and may appeal to patients with insertion anxiety or lifestyle considerations. The extended wear time can also produce more continuous datasets, potentially supporting deeper clinical insights. However, the need for minor surgical procedures for implantation and removal introduces logistical and cost considerations that must be addressed through efficient clinic workflows and training.
Strategically, Senseonics collaborates with larger diabetes care companies for commercialization, allowing it to focus on R&D and clinical validation. Its success will depend on scaling professional training, improving cost-effectiveness, and generating robust real-world evidence. If it can achieve these objectives, the company could carve out a durable niche within the broader CGM market and potentially expand into larger patient segments.
-
AgaMatrix Inc.:
AgaMatrix Inc. is a smaller, innovation-focused company in the Diabetes Care Devices market, primarily active in blood glucose monitoring systems and digital health integration. The company has developed specialized meter technologies and has engaged in co-branding and OEM relationships with larger healthcare companies in the past. Its focus on compact design and smartphone connectivity targets tech-savvy patients seeking convenient monitoring solutions.
In 2025, AgaMatrix’s diabetes device revenue is estimated at USD 0.18 billion, yielding a global market share of roughly 0.40%. These figures position AgaMatrix as a niche player, but one that can influence specific market segments through targeted innovation and partnership models. The revenue base is largely driven by meter and strip sales, complemented by digital app engagement.
AgaMatrix’s strategic strengths include agile product development, willingness to experiment with new connectivity models, and the ability to integrate glucose data into broader smartphone ecosystems. This approach allows the company to appeal to customers who prioritize compact, connected devices over more traditional meter designs. Its OEM capabilities also enable AgaMatrix to embed its technology into other brands’ product portfolios, extending its reach without bearing all commercialization costs.
Going forward, AgaMatrix will need to navigate intense price competition in the BGM space and the structural shift toward CGM. By emphasizing interoperability, app-based analytics, and niche focus on specific patient segments or payer contracts, the company can maintain relevance and potentially become an attractive partner or acquisition target for larger players seeking digital capabilities.
-
Nipro Corporation:
Nipro Corporation is a diversified medical device manufacturer with a significant presence in the Diabetes Care Devices market, particularly in blood glucose monitoring and injection-related products. The company has established a strong foothold in Japan and other Asian markets, and it also serves customers in Europe and other regions through its global distribution network. Nipro’s diabetes offerings focus on reliability and cost-effectiveness, making them suitable for high-volume usage and public health programs.
For 2025, Nipro’s diabetes device revenue is estimated at USD 1.00 billion, representing a global market share of approximately 2.20%. These figures highlight Nipro’s role as a mid-scale player with strong regional dominance and a competitive position in price-sensitive segments. The company’s portfolio often supports government tenders and institutional purchasing where affordability and dependable quality are critical decision factors.
Nipro’s competitive advantages include efficient manufacturing operations, broad experience in disposables, and the ability to tailor products to local regulatory and clinical requirements. Its diabetes portfolio complements its renal care and hospital supply businesses, enabling bundled offerings that appeal to healthcare systems managing multiple chronic conditions. This integrated approach helps Nipro secure long-term contracts and recurring revenue.
Strategically, Nipro is well placed to benefit from the rising prevalence of diabetes in Asia and other emerging markets where infrastructure for advanced technologies like pumps and CGM may be limited. By expanding its digital support tools and aligning with regional telemedicine initiatives, the company can enhance the value proposition of its devices and solidify its standing in growing markets.
-
Arkray Inc.:
Arkray Inc. is a Japanese company with a strong heritage in clinical diagnostics and point-of-care testing, including blood glucose monitoring systems for both professional and home use. In the Diabetes Care Devices market, Arkray offers meters, strips, and other related solutions, with a focus on accuracy, reliability, and ease of use. The company is particularly active in Asia and selected international markets where it competes with both global and regional players.
In 2025, Arkray’s revenue from diabetes care devices is estimated at USD 0.70 billion, which equates to a market share of about 1.54%. These numbers reflect steady participation in the BGM segment, with meaningful sales through pharmacies, hospitals, and government programs. Arkray’s mid-tier scale allows it to maintain a nimble operating model while still achieving economies of scale in manufacturing.
Arkray’s competitive differentiation stems from its diagnostic expertise, including laboratory analyzers and point-of-care devices that complement its glucose monitoring portfolio. This breadth allows the company to provide integrated testing solutions to clinics and hospitals that manage diabetes alongside other chronic diseases. Arkray also invests in localized product development, adapting meter interfaces, language options, and support materials to regional requirements.
As CGM adoption grows, Arkray faces the same structural challenges as other BGM-focused companies. However, its strong presence in professional diagnostics and emerging markets positions it to continue supplying high-volume, cost-effective solutions. Strategic partnerships with digital health platforms and primary care initiatives could further integrate Arkray’s devices into comprehensive chronic disease management programs.
-
Owen Mumford Ltd:
Owen Mumford Ltd is a UK-based medical device company specializing in injection and blood sampling technologies, with a meaningful role in the Diabetes Care Devices market. Its portfolio includes lancets, lancing devices, and pen injection systems designed to improve patient comfort and safety. The company serves both pharmaceutical partners and direct healthcare channels, positioning its products as high-quality alternatives to commodity devices.
For 2025, Owen Mumford’s diabetes-related device revenue is estimated at USD 0.60 billion, corresponding to a market share of around 1.32%. These figures demonstrate a solid niche presence, especially in Europe and selected international markets where the company has long-standing relationships with health systems and pharma companies. The revenue base is driven by recurring demand for consumable lancets and needle-based devices.
Owen Mumford’s strategic advantages include a strong focus on ergonomics, patient experience, and safety engineering. Its devices often reduce pain perception and improve ease of handling, which can enhance adherence to glucose testing and insulin therapy. The company’s collaboration with pharmaceutical firms to develop proprietary pen systems also supports a steady OEM revenue stream and strengthens its role within the broader diabetes ecosystem.
Looking ahead, Owen Mumford can further differentiate by aligning its products with digital adherence tools and remote monitoring platforms. By capturing usage data from injection and sampling devices, the company could support more comprehensive diabetes management insights for clinicians and payers. Its design capabilities and specialized manufacturing give it flexibility to adapt to emerging therapy formats and regulatory requirements.
-
Glooko Inc.:
Glooko Inc. is a digital health company that plays a pivotal data and software role within the Diabetes Care Devices market. Rather than manufacturing hardware, Glooko focuses on aggregating data from multiple devices, including blood glucose meters, CGM systems, insulin pumps, and connected pens, into a unified digital platform. This interoperability enables patients, clinicians, and payers to view and analyze comprehensive diabetes data within a single interface.
In 2025, Glooko’s revenue from diabetes-related digital solutions is estimated at USD 0.50 billion, giving it an approximate market share of 1.10% when considered within the broader Diabetes Care Devices ecosystem, including software-enabled services. While its share may appear modest compared with hardware manufacturers, Glooko’s platform influences a significant portion of device usage by shaping how data are interpreted and used in clinical decision-making.
Glooko’s strategic advantage is rooted in its device-agnostic approach and deep integration capabilities with electronic health records, telemedicine platforms, and payer systems. By normalizing data from disparate devices, the company enables advanced analytics, population health management, and risk stratification. This is increasingly valuable in value-based care models where outcomes and cost metrics drive reimbursement and contracting decisions.
Glooko competes primarily on the quality of its analytics, user experience, and breadth of device integrations. It collaborates with numerous hardware manufacturers, enhancing the attractiveness of their devices by providing robust data management tools. As digital therapeutics and remote monitoring become integral to diabetes care, Glooko’s role as a data orchestrator positions it as a strategic partner to providers, payers, and device companies seeking to demonstrate real-world outcomes and optimize care pathways.
-
Proscigenix Inc.:
Proscigenix Inc. is an emerging company in the Diabetes Care Devices market, focusing on innovative biosensing and digital monitoring technologies. While still in the growth stage compared with established players, Proscigenix aims to develop minimally invasive or non-invasive glucose sensing platforms and integrate them with mobile and cloud-based ecosystems. Its strategy targets patients and providers seeking alternatives to traditional capillary testing and existing wearable sensors.
In 2025, Proscigenix’s revenue from diabetes care devices is estimated at USD 0.10 billion, with a market share of approximately 0.22%. These figures reflect the company’s early commercialization phase, with limited but growing deployments in pilot programs, specialty clinics, and select markets. Despite its small share, Proscigenix’s technologies have the potential to disrupt specific subsegments if clinical validation and manufacturing scale-up proceed successfully.
Proscigenix’s competitive differentiation is based on its R&D capabilities in biosensor chemistry, signal processing, and user-centric digital interfaces. By designing platforms that reduce patient burden and integrate seamlessly with smartphones and telehealth services, the company seeks to address adherence barriers and improve user engagement. Its emphasis on continuous data streams and analytics also aligns with trends toward personalized and predictive diabetes care.
Strategically, Proscigenix will need to secure strong clinical evidence, regulatory approvals, and partnerships with payers and larger device or pharma companies to accelerate adoption. If it can demonstrate superior user experience, cost-effectiveness, or unique clinical insights, the company could find attractive niches in the global market or become a candidate for strategic alliances or acquisition. Its progress will be an important indicator of how emerging biosensing technologies may reshape the future landscape of diabetes care devices.
Key Companies Covered
F. Hoffmann-La Roche Ltd
Abbott Laboratories
Medtronic plc
Dexcom Inc.
Insulet Corporation
Novo Nordisk A/S
Sanofi
Becton Dickinson and Company
Terumo Corporation
Ypsomed Holding AG
Ascensia Diabetes Care
Tandem Diabetes Care Inc.
LifeScan Inc.
Senseonics Holdings Inc.
AgaMatrix Inc.
Nipro Corporation
Arkray Inc.
Owen Mumford Ltd
Glooko Inc.
Proscigenix Inc.
Market By Application
The Global Diabetes Care Devices Market is segmented by several key applications, each delivering distinct operational outcomes for specific industries.
-
Home Healthcare:
Home healthcare represents one of the largest and fastest-growing application segments for diabetes care devices, with a core business objective of enabling patients to manage glycemic control outside institutional settings. This segment heavily utilizes self-monitoring blood glucose meters, continuous glucose monitoring systems, insulin pens, smart insulin pens, and connected apps to reduce hospital dependency and emergency visits. For payers and providers, effective home-based diabetes management can cut diabetes-related hospital admissions by an estimated 15–30%, translating into substantial cost savings over multi-year periods.
The primary justification for adoption in home healthcare is the combination of patient convenience and measurable clinical improvement, as frequent home monitoring and timely insulin titration are associated with lower HbA1c levels and fewer acute complications. Continuous glucose monitoring in the home setting can increase time-in-range by around 10–20 percentage points compared with traditional episodic testing, directly supporting better outcomes and reduced productivity loss for working-age populations. The main growth catalysts include the expansion of telehealth reimbursement, broader availability of connected devices, and demographic aging, which together push health systems to shift chronic disease management from hospitals to the home environment.
Technological enablers such as Bluetooth-enabled meters, cloud-linked insulin pumps, and app-based coaching platforms further accelerate home healthcare deployment by providing clinicians with remote visibility into patient data. Remote monitoring programs allow care teams to proactively intervene when glucose patterns deteriorate, reducing unplanned visits and enabling panel-based management of hundreds of patients versus tens in traditional models. This operational scaling effect, combined with an ROI payback period that can be achieved within one to two years through avoided admissions and complications, reinforces home healthcare as a strategic priority for diabetes care device manufacturers and healthcare organizations.
-
Hospitals:
Hospitals constitute a critical application segment for diabetes care devices, with the primary objective of managing acute glycemic control in inpatients and perioperative settings. Diabetes devices used in hospitals include point-of-care blood glucose meters, continuous glucose monitoring systems for select high-risk patients, insulin pumps for existing users, and infusion-based insulin protocols. Effective inpatient glycemic management can reduce length of stay by an estimated 0.5–1.0 days for certain diagnostic groups and lower postoperative infection rates, which directly impacts bed turnover and financial performance.
Adoption in hospitals is justified by the operational and clinical benefits of standardized glucose monitoring and insulin delivery pathways, particularly in intensive care units and surgical wards. Protocol-driven use of point-of-care testing and insulin delivery has been associated with reduced hypoglycemia episodes and more stable glucose ranges, leading to fewer complications and readmissions. Hospitals increasingly deploy integrated glucose management systems that automatically upload bedside meter readings into electronic health records, reducing documentation time by 20–30% and decreasing transcription errors.
The primary growth catalyst within hospital applications is the tightening of clinical quality metrics and reimbursement models that penalize avoidable complications and extended stays. Regulatory and accreditation bodies emphasize glucose control as a key quality indicator, prompting hospitals to invest in more accurate meters, continuous glucose monitoring for specific cohorts, and decision support tools. In addition, the rise of hospital-wide digitalization, including closed-loop integration between devices and electronic health records, drives demand for interoperable, enterprise-grade diabetes care technologies that fit into broader clinical information systems.
-
Clinics and Outpatient Centers:
Clinics and outpatient centers play a central role in ongoing diabetes management, focusing on regular follow-up, therapy adjustment, and patient education rather than acute care. In this application, diabetes care devices such as point-of-care HbA1c analyzers, blood glucose meters, continuous glucose monitoring review stations, and insulin titration tools are used to optimize treatment plans during scheduled visits. Effective use of these tools in outpatient settings can improve guideline adherence and reduce long-term complication risk, contributing to measurable declines in emergency visits and inpatient admissions.
The justification for adoption in clinics lies in their ability to deliver high-throughput, standardized evaluations within limited consultation times. For example, point-of-care HbA1c testing can provide results within 5–10 minutes, enabling real-time therapy adjustments in a single visit and improving follow-through compared with off-site lab testing. Clinics that implement structured device-based monitoring protocols can increase the proportion of patients achieving target HbA1c levels by an estimated 10–20 percentage points over time, which aligns with payer incentives and quality-based reimbursement programs.
Growth in this segment is fueled by the expansion of multidisciplinary diabetes centers, increasing prevalence of prediabetes screening programs, and the shift toward population health management. Outpatient providers are adopting integrated software platforms that aggregate data from patient-owned devices, allowing clinicians to review weeks of glucose and insulin activity during brief appointments. This data-driven workflow enhances clinician productivity and helps outpatient centers manage larger patient panels without proportionally increasing staffing, reinforcing investment in connected diabetes care technologies.
-
Diagnostic Centers:
Diagnostic centers serve as specialized hubs for laboratory and point-of-care testing, focusing on early detection, staging, and ongoing evaluation of diabetes and related metabolic disorders. Their core business objective in the diabetes care devices market is to deliver high-throughput, high-accuracy tests such as fasting glucose, oral glucose tolerance testing, and HbA1c analysis. By leveraging automated analyzers and standardized protocols, diagnostic centers can process hundreds or thousands of samples per day, providing rapid turnaround that supports timely diagnosis and therapy initiation.
Adoption of diabetes-related testing technologies in diagnostic centers is justified by the operational efficiency gained through automation and consolidated sample processing. Modern high-volume analyzers can increase throughput by 30–50% compared with older platforms, while reducing per-test labor requirements and reagent waste. This enables diagnostic centers to maintain competitive pricing while delivering consistent quality, which is essential for contracts with hospitals, clinics, and employer-sponsored screening programs.
The primary catalyst driving growth in this application segment is the global push for earlier detection of diabetes and prediabetes, driven by epidemiological evidence and payer strategies to contain long-term complications. Population-level screening initiatives, corporate wellness programs, and government-led preventive health campaigns all generate additional demand for glucose and HbA1c testing. As diagnostic centers invest in connected reporting tools that interface with electronic health records and patient portals, they further enhance their role in longitudinal diabetes monitoring and attract more referral volume from providers seeking integrated diagnostic workflows.
-
Ambulatory Surgical Centers:
Ambulatory surgical centers represent a specialized application segment where diabetes care devices are used to manage perioperative glycemic control in patients undergoing same-day procedures. The core business objective is to minimize surgical risk and postoperative complications associated with hyperglycemia or hypoglycemia in a cost-efficient, high-throughput setting. Point-of-care blood glucose meters and protocol-driven insulin administration tools are commonly used to ensure that glucose levels remain within targeted ranges before, during, and immediately after procedures.
The justification for adopting diabetes care devices in ambulatory surgical centers is grounded in their impact on surgical throughput and patient safety. Maintaining stable perioperative glucose can reduce the incidence of postoperative infections and unplanned hospital admissions, thereby preserving the expected same-day discharge rate that underpins the economic model of these centers. Studies in similar settings have shown that structured glucose management can cut perioperative complication rates by 10–20%, which directly supports quality metrics and payer satisfaction.
Growth in this segment is fueled by the broader shift of surgical procedures from hospitals to ambulatory environments, driven by cost pressures and advances in minimally invasive techniques. As a higher proportion of surgical patients present with diabetes or prediabetes, ambulatory surgical centers must implement standardized glucose management protocols supported by reliable point-of-care devices. Regulatory emphasis on perioperative safety and accreditation requirements further encourage investment in robust diabetes monitoring tools that integrate seamlessly into preoperative and postoperative workflows.
-
Long-term Care Facilities:
Long-term care facilities, including nursing homes and assisted living centers, form an important application segment where diabetes care devices support chronic glycemic management for elderly and multi-morbid patients. The core business objective is to stabilize glucose levels over the long term, thereby reducing acute events such as hypoglycemic episodes and hospital transfers that disrupt care and increase costs. Devices used in this setting range from simple blood glucose meters and lancets to select continuous glucose monitoring systems for high-risk residents.
Adoption in long-term care facilities is justified by the operational advantages of standardized monitoring protocols and simplified insulin administration regimens. Regular use of point-of-care glucose testing can help nursing staff detect trends and adjust diets or medications, reducing emergency transfers by an estimated 10–25% in well-managed facilities. Simplified insulin delivery methods, such as prefilled pens, can decrease administration time per resident and lower medication errors compared with vial-and-syringe approaches, improving both safety and staff productivity.
The primary growth catalyst in this application segment is demographic aging, with a rising share of residents living with diabetes or complex metabolic syndromes. Regulatory scrutiny of care quality in long-term facilities, including penalties for avoidable hospitalizations and adverse drug events, pushes operators to adopt more structured diabetes care protocols supported by reliable devices. Additionally, integration of device data into facility-wide electronic health record systems enables better care coordination, auditability, and risk management, making technology-enabled diabetes management an increasingly strategic investment for long-term care operators.
-
Academic and Research Institutes:
Academic and research institutes represent a high-value, innovation-focused application segment for diabetes care devices, with the primary objective of developing and validating new technologies, therapies, and care models. These institutions use advanced continuous glucose monitoring systems, experimental sensor platforms, insulin pumps, smart pens, and analytical software to conduct clinical trials and translational research. Their work often informs regulatory approvals, reimbursement decisions, and clinical guidelines, giving this segment outsized influence relative to its direct device purchasing volume.
Adoption of sophisticated diabetes care devices in academic and research settings is justified by the need for high-resolution data and precise control in experimental protocols. For instance, continuous glucose monitoring systems that collect readings every few minutes can generate tens of thousands of data points per participant per trial, enabling detailed analysis of time-in-range, variability, and response to interventions. Integration with research-grade analytics platforms allows investigators to quantify endpoints such as percentage reduction in hypoglycemic events or improvement in mean glucose levels with high statistical power, which is essential for demonstrating clinical and economic value.
The primary growth catalyst in this segment is the accelerating pace of innovation in digital health, biosensors, and automated insulin delivery, which requires rigorous evaluation before widespread clinical deployment. Funding from governments, foundations, and industry sponsors supports large-scale trials involving thousands of participants, driving demand for standardized, research-compatible device ecosystems. As academic and research institutes increasingly collaborate with device manufacturers and healthcare systems, they also help define interoperability standards and real-world evidence frameworks, shaping the long-term trajectory of the global diabetes care devices market.
Key Applications Covered
Home Healthcare
Hospitals
Clinics and Outpatient Centers
Diagnostic Centers
Ambulatory Surgical Centers
Long-term Care Facilities
Academic and Research Institutes
Mergers and Acquisitions
The Diabetes Care Devices Market has experienced an active mergers and acquisitions cycle over the past 24 months, driven by the need to scale connected care platforms and expand recurring revenue from consumables. Strategic buyers have focused on consolidating continuous glucose monitoring, insulin delivery and digital coaching capabilities into integrated ecosystems. This deal flow reflects a shift toward end-to-end diabetes management solutions that combine hardware, software and data analytics to lock in patients, deepen provider relationships and capture a larger share of long-term device and sensor spending.
Major M&A Transactions
Dexcom – Tidepool
Integrating interoperable insulin dosing software to strengthen patient-centric CGM decision support.
Abbott Laboratories – Bigfoot Biomedical
Expanding smart insulin delivery offerings around Freestyle CGM to build closed-loop therapy systems.
Medtronic – EOFlow
Adding patch pump technology to accelerate next-generation automated insulin delivery portfolios globally.
Roche – mySugr Minority Buyout
Consolidating digital diabetes coaching assets to enhance data-driven therapy optimization.
Insulet – Small CGM Algorithm Startup
Gaining proprietary analytics engines to refine closed-loop insulin dosing accuracy and safety.
Ypsomed – CamDiab Partnership Equity
Securing algorithm control to differentiate hybrid closed-loop insulin pump platforms.
Ascensia Diabetes Care – GlucoMe Assets
Acquiring connected BGM technologies to defend share against CGM-led displacement.
Terumo – Asia-based Insulin Pen Maker
Strengthening injectable device portfolio and regional distribution in fast-growing markets.
Recent consolidation is reshaping competitive dynamics by concentrating innovation and scale within a handful of global diabetes technology leaders. Large acquirers are combining CGM sensors, insulin pumps, smart pens and digital therapeutics into unified platforms, which increases switching costs and narrows room for standalone device vendors. As these ecosystems deepen, bargaining power shifts toward integrated suppliers that can negotiate formulary access and value-based contracts with payers and health systems.
Valuation multiples in diabetes care devices have remained elevated relative to broader medtech benchmarks, reflecting the market’s sustained growth trajectory. The Diabetes Care Devices Market is projected to grow from USD 45.60 Billion in 2025 to USD 49.20 Billion in 2026 and reach USD 76.90 Billion by 2032, supported by a 7.80% CAGR. Strategic buyers are therefore willing to pay premium revenue multiples for assets that add differentiated algorithms, digital engagement or high-margin sensor consumables, since these capabilities magnify lifetime value per patient.
Another critical theme is the use of M&A to accelerate time-to-market for next-generation closed-loop systems. Rather than relying solely on internal R&D, incumbents increasingly purchase proven software, cybersecurity and data science capabilities to secure regulatory approvals faster. This approach reduces development risk, supports premium pricing and enhances reimbursement narratives around improved glycemic outcomes and reduced hospitalizations, which are central to long-term value creation in this therapy area.
Regionally, North America and Western Europe continue to dominate larger transactions as reimbursement frameworks favor CGM and automated insulin delivery adoption. However, rising deal activity in Asia-Pacific targets manufacturing footprints, cost-optimized devices and distribution access for rapidly growing type 2 diabetic populations. These bolt-on acquisitions position global players to serve middle-income segments with localized product configurations and pricing while maintaining global technology standards.
Technology-driven themes are equally decisive in the mergers and acquisitions outlook for Diabetes Care Devices Market, with acquirers prioritizing AI-enabled decision support, hospital-to-home data integration and interoperable platforms. Targets offering cloud-based analytics, dose titration algorithms and real-time population management tools are receiving particular interest, as buyers seek capabilities that convert device data into reimbursable, outcomes-focused services and strengthen competitive moats against new digital health entrants.
Competitive LandscapeRecent Strategic Developments
In January 2024, a leading insulin pump manufacturer completed an acquisition of a European patch-pump startup, adding tubeless wearable technology to its portfolio. This acquisition type development significantly intensified competition in the insulin delivery segment by combining established reimbursement networks with next-generation, smartphone-connected patch pumps, accelerating the shift from multiple daily injections to automated insulin delivery systems.
In April 2023, a major continuous glucose monitoring (CGM) company entered a strategic partnership with a global cloud provider to co-develop an integrated data platform. This collaboration, structured as a strategic investment in digital infrastructure, enabled real-time analytics, predictive glycemic modeling and remote patient monitoring, pushing the market toward data-driven population health management and value-based diabetes care contracts with payers.
In September 2023, a large diagnostics firm announced a manufacturing expansion in Southeast Asia for blood glucose meters and test strips. This capacity expansion focused on high-volume, cost-optimized production, improving price accessibility in emerging markets and forcing incumbents to reassess pricing, local sourcing and channel strategies for point-of-care diabetes testing products.
SWOT Analysis
-
Strengths:
The global Diabetes Care Devices market benefits from strong underlying epidemiological demand driven by rising type 1 and type 2 diabetes prevalence, aging populations, and growing obesity rates, which sustain consistent volume growth for glucose monitors, insulin pumps, smart pens, and continuous glucose monitoring systems. Technological innovation is a core strength, with sensor miniaturization, closed-loop insulin delivery, cloud connectivity, and AI-driven decision support improving time-in-range and patient adherence, while enabling remote monitoring and tele-endocrinology workflows. Established manufacturers maintain robust regulatory experience, quality systems, and distribution networks, which support reliable product supply and post-market surveillance across North America, Europe, and increasingly Asia-Pacific. Reimbursement frameworks in major markets for CGM and insulin pump therapy, combined with recurring consumables revenue from sensors, test strips, and infusion sets, reinforce predictable cash flows and support ongoing research and development, portfolio expansion, and clinician education programs that further entrench incumbent device platforms in routine diabetes management pathways.
-
Weaknesses:
The Diabetes Care Devices market faces structural weaknesses related to high device and consumable costs, which limit access in low- and middle-income countries and create reimbursement pressure even in developed healthcare systems. Fragmented user experiences, where patients juggle separate glucometers, insulin delivery systems, and digital apps, can reduce adherence and increase training burden for clinicians, particularly in primary care settings with limited diabetes education resources. Supply chain complexity for sensors, microelectronics, and sterile components exposes manufacturers to shortages, quality deviations, and recalls that can disrupt therapy continuity and erode provider trust. Additionally, steep learning curves for advanced insulin pumps and hybrid closed-loop systems, coupled with fears of hypoglycemia and alarm fatigue, inhibit adoption among elderly patients and technology-averse populations, leaving a sizable segment reliant on suboptimal fingerstick testing and multiple daily injections despite the availability of more advanced diabetes care devices.
-
Opportunities:
The market has substantial opportunities in emerging economies, where rising incomes and expanding insurance coverage can unlock new demand for affordable continuous glucose monitoring, connected glucometers, and simplified patch pumps tailored to high-volume public health programs. Integration of diabetes care devices with digital health platforms, electronic medical records, and population health analytics enables risk stratification, proactive outreach, and outcome-based contracts with payers, positioning device manufacturers as partners in comprehensive chronic disease management rather than commodity suppliers. There is also significant runway for expansion in type 2 diabetes patients currently managed only with oral therapies, where intermittent CGM, smart insulin titration, and remote coaching can delay complications and reduce hospitalizations. Strategic collaborations with pharmaceutical companies for combination device–drug solutions, such as insulin plus GLP-1 regimens guided by real-time data, create additional differentiation and support premium pricing in an otherwise cost-sensitive therapeutic area.
-
Threats:
The Diabetes Care Devices market is exposed to threats from intensifying price competition, tender-based procurement, and reference pricing policies that compress margins on test strips, sensors, and commoditized glucometers. Regulatory bodies are tightening cybersecurity, data privacy, and interoperability requirements for connected devices, increasing compliance costs and extending approval timelines for new features and software updates. Rapid entry of low-cost regional manufacturers, particularly in Asia, challenges incumbent brands with aggressive pricing and localized distribution, potentially accelerating commoditization of basic monitoring devices. Furthermore, clinical advances in disease-modifying therapies, weight-loss drugs, and potential cell-based or gene-editing approaches could, over time, reduce the addressable volume for traditional glucose testing and insulin delivery, particularly if they significantly lower insulin requirements or delay progression from prediabetes to overt type 2 diabetes, thereby altering long-term demand dynamics for diabetes care devices.
Future Outlook and Predictions
The global Diabetes Care Devices market is expected to follow a sustained growth trajectory over the next decade, supported by strong epidemiological and economic fundamentals. ReportMines data indicates the market will grow from USD 45.60 Billion in 2025 to USD 49.20 Billion in 2026 and is projected to reach USD 76.90 Billion by 2032, reflecting a compound annual growth rate of 7.80%. This pace suggests steady expansion rather than explosive growth, driven by rising diabetes prevalence, aging populations, and expanding access to diagnostic and monitoring technologies in emerging economies.
Technology evolution will center on continuous glucose monitoring and automated insulin delivery, gradually displacing standalone blood glucose meters and basic insulin pens in many developed markets. Sensor accuracy, wear-time, and calibration-free operation will continue to improve, while fully closed-loop systems will move from early adopters to broader patient segments. Over the next 5–10 years, interoperability between CGM sensors, insulin pumps, smart pens, and smartphone apps will become a key differentiator, as payers and providers favor integrated ecosystems that deliver better time-in-range metrics and reduced acute complication rates.
Data-driven diabetes management will become a primary growth engine, as cloud platforms and analytics transform device data into actionable clinical insights. Real-time dashboards, risk scores, and automated alerts will enable remote patient monitoring at scale, allowing endocrinology practices and primary care networks to manage larger diabetes populations with limited staff. These capabilities will support value-based reimbursement models, where device manufacturers are increasingly judged on reductions in hospitalizations, hypoglycemic events, and long-term complication costs rather than unit sales alone.
Regulatory and reimbursement environments will play a critical role in shaping adoption patterns, particularly for advanced devices. Authorities are likely to tighten standards related to cybersecurity, software updates, and interoperability for connected diabetes care devices, lengthening development cycles but also raising the barrier to entry for low-quality competitors. At the same time, broader reimbursement for CGM in type 2 diabetes, pediatric populations, and high-risk prediabetes cohorts will expand the addressable market, provided manufacturers can demonstrate measurable outcome improvements in real-world evidence studies.
Competitive dynamics will intensify as established multinationals, regional manufacturers, and digital health entrants converge on the same patient pathways. Leading players will focus on ecosystem lock-in through proprietary data platforms, subscription models for sensors and software, and partnerships with pharmaceutical companies to create integrated device–drug solutions. In parallel, cost-optimized meters, strips, and basic CGM solutions will proliferate in price-sensitive markets, forcing global brands to localize manufacturing, simplify product designs, and adopt tiered portfolios that balance innovation with affordability.
Table of Contents
- Scope of the Report
- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- Executive Summary
- 2.1 World Market Overview
- 2.1.1 Global Diabetes Care Devices Annual Sales 2017-2028
- 2.1.2 World Current & Future Analysis for Diabetes Care Devices by Geographic Region, 2017, 2025 & 2032
- 2.1.3 World Current & Future Analysis for Diabetes Care Devices by Country/Region, 2017,2025 & 2032
- 2.2 Diabetes Care Devices Segment by Type
- Self-Monitoring Blood Glucose Devices
- Continuous Glucose Monitoring Devices
- Insulin Pens
- Insulin Pumps
- Smart Insulin Pens
- Insulin Syringes
- Lancets and Lancing Devices
- Diabetes Management Software and Apps
- Sensor-Based Insulin Delivery Systems
- Blood Glucose Test Strips
- 2.3 Diabetes Care Devices Sales by Type
- 2.3.1 Global Diabetes Care Devices Sales Market Share by Type (2017-2025)
- 2.3.2 Global Diabetes Care Devices Revenue and Market Share by Type (2017-2025)
- 2.3.3 Global Diabetes Care Devices Sale Price by Type (2017-2025)
- 2.4 Diabetes Care Devices Segment by Application
- Home Healthcare
- Hospitals
- Clinics and Outpatient Centers
- Diagnostic Centers
- Ambulatory Surgical Centers
- Long-term Care Facilities
- Academic and Research Institutes
- 2.5 Diabetes Care Devices Sales by Application
- 2.5.1 Global Diabetes Care Devices Sale Market Share by Application (2020-2025)
- 2.5.2 Global Diabetes Care Devices Revenue and Market Share by Application (2017-2025)
- 2.5.3 Global Diabetes Care Devices Sale Price by Application (2017-2025)
Frequently Asked Questions
Find answers to common questions about this market research report